Ongoing challenges for pharmacotherapy for dyslipidemia

Anthony D. Pisaniello, Daniel J. Scherer, Yu Kataoka, Stephen J. Nicholls

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Introduction: While increasing evidence has led to lipid-modifying therapy achieving an important role in the treatment guidelines for the prevention of cardiovascular disease, these agents are suboptimally used and there remains a considerable risk of clinical events. Accordingly, there is a need to develop more effective lipid-modifying approaches in many patients. Areas covered: A literature search was performed of topical manuscripts focusing on factors influencing use of established therapies and new agents in development that target a range of lipid factors. Expert opinion: More intensive efforts are required to ensure that statin use is maximized in higher risk patients. A range of novel therapies, including proprotein convertase subtilisin kexin-type 9 and cholesteryl ester transfer protein inhibitors, may provide additional protection, although this remains to be established by clinical trials.

LanguageEnglish
Pages347-356
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Volume16
Issue number3
DOIs
Publication statusPublished - 1 Jan 2015

Keywords

  • Atherosclerosis
  • Cardiovascular risk
  • Lipid-modifying therapy
  • Lipids

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pisaniello, A. D., Scherer, D. J., Kataoka, Y., & Nicholls, S. J. (2015). Ongoing challenges for pharmacotherapy for dyslipidemia. Expert Opinion on Pharmacotherapy, 16(3), 347-356. https://doi.org/10.1517/14656566.2014.986094